AU523705B2 - N-acetyl taurine salts - Google Patents

N-acetyl taurine salts

Info

Publication number
AU523705B2
AU523705B2 AU34634/78A AU3463478A AU523705B2 AU 523705 B2 AU523705 B2 AU 523705B2 AU 34634/78 A AU34634/78 A AU 34634/78A AU 3463478 A AU3463478 A AU 3463478A AU 523705 B2 AU523705 B2 AU 523705B2
Authority
AU
Australia
Prior art keywords
taurine
acetyl
per
active ingredient
lithium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU34634/78A
Other languages
English (en)
Other versions
AU3463478A (en
Inventor
Borlace Jeanpierre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LES LABORATORIES MERAM
Original Assignee
Cooperation Pharmaceutique Francaise SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cooperation Pharmaceutique Francaise SAS filed Critical Cooperation Pharmaceutique Francaise SAS
Publication of AU3463478A publication Critical patent/AU3463478A/en
Application granted granted Critical
Publication of AU523705B2 publication Critical patent/AU523705B2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU34634/78A 1977-03-23 1978-03-31 N-acetyl taurine salts Expired AU523705B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR7708692 1977-03-23
FR7708692A FR2384751A1 (fr) 1977-03-23 1977-03-23 Nouveaux derives de la taurine a activite neuro-musculaire renforcee

Publications (2)

Publication Number Publication Date
AU3463478A AU3463478A (en) 1979-10-04
AU523705B2 true AU523705B2 (en) 1982-08-12

Family

ID=9188473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34634/78A Expired AU523705B2 (en) 1977-03-23 1978-03-31 N-acetyl taurine salts

Country Status (17)

Country Link
US (3) US4199601A (enExample)
JP (1) JPS53149928A (enExample)
AT (1) AT356637B (enExample)
AU (1) AU523705B2 (enExample)
BE (1) BE865163A (enExample)
CA (1) CA1095930A (enExample)
CH (1) CH629479A5 (enExample)
DE (1) DE2810918C2 (enExample)
ES (1) ES468201A1 (enExample)
FR (1) FR2384751A1 (enExample)
GB (1) GB1599962A (enExample)
GR (1) GR62093B (enExample)
IT (1) IT1111455B (enExample)
NL (1) NL7803131A (enExample)
OA (1) OA05914A (enExample)
SE (1) SE443781B (enExample)
ZA (1) ZA781697B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4915685A (en) * 1986-03-19 1990-04-10 Petelenz Tomasz J Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US6099869A (en) 1995-04-18 2000-08-08 Nutrition 21 Calcium taurate and antihypertensive drug for hypertension
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
ATE251129T1 (de) * 1998-01-27 2003-10-15 Merck Sante Sas Derivatives of aminoalkane sulphonic, phosphonic and phosphinic acids, their preparation and their use as medicaments
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6881750B2 (en) * 2003-03-04 2005-04-19 Nutrition Corp. Of America, Ltd. Potassium taurate bicarbonate and ascorbate
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2005310986A1 (en) * 2004-11-12 2006-06-08 Bellus Health (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
FR2878160B1 (fr) * 2004-11-19 2008-07-25 Jean Pierre Durlach Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique
EP1836161B1 (en) * 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
TW200924746A (en) * 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
FR2927809B1 (fr) 2008-02-26 2011-01-14 Tri Inov Nouvelle utilisation de n-acetyl-taurinate de zinc.
RU2453310C1 (ru) * 2010-12-09 2012-06-20 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Средство, обладающее нейропротекторным действием в условиях ишемического поражения мозга и гипоксии, представляющее собой 2-аминоэтансульфонат магния, фармацевтические композиции
FR2973702B1 (fr) 2011-04-08 2013-04-26 Tri Inov N-acetyl-taurinate de zinc pour le traitement du cancer de la prostate
BR112014012918A2 (pt) * 2011-11-29 2017-06-13 Basf Se processo para preparar um sal de ácido, ácido, sal de sódio ácido, e, uso de um ácido
MX365366B (es) 2015-06-17 2019-05-30 Jean Profet Margaret Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
CN112516123B (zh) * 2015-12-25 2022-07-19 北京乳凝创智生物技术研发中心（有限合伙） 一种保健品外用制剂
BE1025644B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale
BE1025645B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement de la neurotoxicite due a l'hyperexcitabilite des recepteurs glutamatergiques ionotropes
EP3738588A1 (en) 2019-05-13 2020-11-18 Margaret Jean Profet Topical and oral formulations comprising taurine and magnesium for use in the treatment of rosacea
WO2020229443A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel
ES2917623T3 (es) 2019-05-16 2022-07-11 Synapharm Ind Synthesis Compuesto y composición para uso en el tratamiento del síndrome premenstrual y/o del trastorno disfórico premenstrual
BE1026955B1 (fr) * 2019-06-11 2020-08-04 Synapharm Ind Synthesis Procédé de fabrication de N-acétyl-taurinate de magnésium
RU2730835C1 (ru) * 2019-10-23 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Дикалиевая соль N-(3-гидроксибензоил)таурина, обладающая антиагрегантной и антитромботической активностью в сочетании с церебропротективным действием
RU2731106C1 (ru) * 2019-10-23 2020-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Дикалиевая соль N-(4-гидроксибензоил)таурина, обладающая антиагрегантной и антитромботической активностью
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
WO2026013679A1 (en) * 2024-07-11 2026-01-15 Celagenex Research (India) Pvt. Ltd. A conjugate compound for regulation of mbp expression and novel in-situ process for preparation thereof.
CN119504517B (zh) * 2025-01-22 2025-04-18 浙江天启生化股份有限公司 一种乙酰牛磺酸镁的制备方法
WO2026162765A1 (en) * 2025-01-31 2026-08-06 Synapharm Industrial Synthesis Compound and compositions for weight management and related conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232968A (en) * 1959-12-01 1966-02-01 Gen Aniline & Film Corp Process for preparing n-acyl taurates using hypophosphorous acid as catalyst
US3344174A (en) * 1962-08-21 1967-09-26 Monsanto Co Vicinal acylamido sulfonate compounds
DE1256650B (de) * 1965-08-07 1967-12-21 Dr Dieter Arlt Verfahren zur Herstellung von N-acylierten 2-Amino-alkan-sulfonsaeuren-(1) bzw. von 2-Amino-alkan-sulfonsaeuren-(1)
US3544597A (en) * 1969-06-12 1970-12-01 Rohm & Haas Process for manufacturing sulfonated amides
US3960918A (en) * 1973-06-26 1976-06-01 The Lubrizol Corporation Preparation of esters of amidoalkanesulfonic acids

Also Published As

Publication number Publication date
AT356637B (de) 1980-05-12
IT1111455B (it) 1986-01-13
JPS53149928A (en) 1978-12-27
GR62093B (en) 1979-02-22
ZA781697B (en) 1979-03-28
IT7867631A0 (it) 1978-03-22
OA05914A (fr) 1981-06-30
SE443781B (sv) 1986-03-10
FR2384751A1 (fr) 1978-10-20
DE2810918C2 (de) 1985-06-20
CA1095930A (en) 1981-02-17
NL7803131A (nl) 1978-09-26
GB1599962A (en) 1981-10-07
ES468201A1 (es) 1978-12-01
BE865163A (fr) 1978-09-22
US4271189A (en) 1981-06-02
JPS6256867B2 (enExample) 1987-11-27
SE7803032L (sv) 1978-09-24
ATA202878A (de) 1979-10-15
US4199601A (en) 1980-04-22
FR2384751B1 (enExample) 1979-07-20
DE2810918A1 (de) 1978-09-28
CH629479A5 (fr) 1982-04-30
AU3463478A (en) 1979-10-04
US4267194A (en) 1981-05-12

Similar Documents

Publication Publication Date Title
AU3463478A (en) N-acetyl taurine salts
AU522716B2 (en) Acylanilide derivatives
AU524339B2 (en) Tripherylalkene derivatives
AU514354B2 (en) N-(substituted aminoalkyl)-2-oxo-1-pyrrolidineacetamides
AU4273578A (en) Amine derivatives
AU3938978A (en) Thienothiazine derivatives
AU541144B2 (en) Aminoalkylbenzene derivatives
AU512266B2 (en) M-trifluoromethylphenylpiperazine derivatives
AU3409978A (en) 4-acylaminophenyl-ethanolamines
AU523183B2 (en) Ethoxygquin derivatives
AU515458B2 (en) Antioestrogenic phenylbut-1-ene derivatives
AU512057B2 (en) Meta-sulfonamido-benzamide derivatives
AU520334B2 (en) 25-alkylcholesterol derivatives
AU3285878A (en) Oxadiazolopyrimidine derivatives
AU520682B2 (en) Lipogensis inhibitors
AU519005B2 (en) Phenylacycloakane derivatives
AU521883B2 (en) Pyranochromone derivatives
AU502293B1 (en) 4-amino-oleandomycin derivatives
AU517387B2 (en) Tetracyclononane derivatives
AU2439877A (en) Timing unit
AU519292B2 (en) NEW 3-AMINO-17a azad-HOMOANDROSTONE DERIVATIVES
AU519998B2 (en) Benzenesulfonamide derivatives
AU3598578A (en) Fortimicing derivatives
AU520254B2 (en) N-epsilon-trimethyl-l-lysine salts
AU520739B2 (en) Lipogensis inhibitors